Epitalon Cardiovascular Impact Long-Term: What the Evidence Actually Shows

What did the human studies measure?

FDA found three human studies of epitalon: two sublingual studies in night-shift workers and one eye injection in retinitis pigmentosa [1]. A 2026 narrative review concluded that human evidence is limited to small physiological or biomarker studies and an older controlled retina study, that no adequately powered randomized trial has established efficacy, and that pharmacokinetic, dose-ranging and long-term safety data are inadequate; it called epitalon 'biologically active but clinically unproven' [3].

The one study with a pineal marker was placebo-controlled and short. Of 75 healthy women aged 40 to 50 enrolled, mostly night-shift workers, 40 with low melatonin output were split into two groups of 20 and given a sublingual spray delivering about 0.5 mg per day or placebo for 20 days. Urinary 6-sulfatoxymelatonin rose about 1.7-fold with epitalon and did not change with placebo, and 83% versus 25% were described as improved in mood and physical condition; no sleep outcomes were measured and blinding was not specified [1].

The telomere result comes from cells in a dish

In 2003, Khavinson and colleagues added epitalon to cultures of telomerase-negative human fetal fibroblasts; the cells expressed the catalytic subunit of telomerase, showed telomerase activity, and their telomeres elongated [2]. That is a cell-culture result, not a measurement in an artery or in a person.

In populations, shorter leukocyte telomeres do track with coronary risk. A meta-analysis of 24 studies and 43,725 participants, 8,400 of them with cardiovascular disease, found a relative risk for coronary heart disease of 1.54 (95% CI 1.30 to 1.83) in the shortest versus the longest third of leukocyte telomere length [4]. That is an association between naturally occurring telomere length and disease, not evidence that lengthening telomeres with a drug prevents heart disease.

Safety, approval status and dose

FDA found no clinical study that assessed epitalon's safety and no clinical data supporting its safety [1]. Its adverse-event database search through 8 December 2025 and supplement complaint search through 5 December 2025 retrieved no epitalon reports [1]. FDA described a mechanistic potential for epitalon to be carcinogenic, because it activates telomerase and longer telomeres are generally linked to higher cancer risk, and said the mouse cancer and chromosome-damage studies were too limited to show safety: one fixed dose, female mice only, short exposure [1]. FDA also raised an immunogenicity concern for subcutaneous injection [1]; its compounding safety-risk page says injectable peptides may pose immunogenicity risk from aggregation and impurities [5]. FDA found no pharmacokinetic data [1].

Epitalon is not FDA-approved and has no approved dose [1]. Seller sites FDA reviewed suggest 5 mg to 10 mg per day in cycles, which FDA treated as marketing rather than evidence; the human studies it found used about 0.5 mg per day by sublingual spray and an injection beside the eye [1].